Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML.

MLA

Albert, Daniel H., et al. “Co-Clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML.” In Vivo (Athens, Greece), vol. 36, no. 4, July 2022, pp. 1615–27. EBSCOhost, https://doi.org/10.21873/invivo.12872.

APA

Albert, D. H., Goodwin, N. C., Davies, A. M., Rowe, J., Feuer, G., Boyiadzis, M., Dorritie, K. A., Mancini, M., Gandour-Edwards, R., Jonas, B. A., Borthakur, G., Aldoss, I., Rizzieri, D. A., Odenike, O., Prebet, T., Singh, S., Popovic, R., Shen, Y. U., McDaniel, K. F., … Frost, D. J. (2022). Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML. In Vivo (Athens, Greece), 36(4), 1615–1627. https://doi.org/10.21873/invivo.12872

Chicago

Albert, Daniel H, Neal C Goodwin, Angela M Davies, Jenny Rowe, Gerold Feuer, Michael Boyiadzis, Kathleen A Dorritie, et al. 2022. “Co-Clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML.” In Vivo (Athens, Greece) 36 (4): 1615–27. doi:10.21873/invivo.12872.